scholarly article | Q13442814 |
P50 | author | Marja-Riitta Taskinen | Q18246437 |
Markku Laakso | Q28050161 | ||
Paul P. Glasziou | Q38799353 | ||
P2093 | author name string | Scott R | |
Barter P | |||
Best J | |||
Colman P | |||
d'Emden M | |||
Davis T | |||
Drury P | |||
Ehnholm C | |||
Forder P | |||
Hunt D | |||
Keech A | |||
Kesäniemi YA | |||
Pillai A | |||
Simes RJ | |||
Sullivan D | |||
Whiting M | |||
P2860 | cites work | Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial | Q44459441 |
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial | Q44599698 | ||
Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. | Q44798929 | ||
Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. | Q51621111 | ||
Dynamic balanced randomization for clinical trials. | Q52386670 | ||
WHO clofibrate/cholesterol trial: clarifications | Q67523931 | ||
Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics | Q69912439 | ||
Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study | Q74507662 | ||
Fenofibrate increases creatininemia by increasing metabolic production of creatinine | Q78354361 | ||
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design | Q24569560 | ||
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples | Q24569561 | ||
The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481] | Q24804541 | ||
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481] | Q24815913 | ||
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome | Q28252498 | ||
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | Q29622926 | ||
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial | Q33966645 | ||
Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). | Q34161324 | ||
Effect of different antilipidemic agents and diets on mortality: a systematic review | Q34410711 | ||
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease | Q34687253 | ||
Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes | Q34778046 | ||
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia | Q34820339 | ||
Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis | Q34974714 | ||
Diabetic dyslipidaemia: from basic research to clinical practice. | Q35139885 | ||
Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. | Q36756284 | ||
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study | Q41840439 | ||
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). | Q44128229 | ||
P433 | issue | 9500 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | circulatory system | Q11068 |
type 2 diabetes | Q3025883 | ||
P304 | page(s) | 1849-61 | |
P577 | publication date | 2005-11-26 | |
P1433 | published in | The Lancet | Q939416 |
P1476 | title | Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial | |
P478 | volume | 366 |
Q43063699 | "Why is it always the heart which suffers from myocardial infarction?" The "Marburg hypothesis" of the pathogenesis of atherosclerosis |
Q37435149 | 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations |
Q38071039 | 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American |
Q28301815 | 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines |
Q26747559 | 2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation) |
Q49396285 | 2016 Chinese guidelines for the management of dyslipidemia in adults. |
Q48123127 | 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document |
Q98613612 | 2018 Guidelines for the Management of Dyslipidemia in Korea |
Q91611086 | 2018 Guidelines for the management of dyslipidemia |
Q51743168 | A Clinical Guide to Combination Lipid-Lowering Therapy. |
Q26752487 | A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD |
Q91362103 | A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury |
Q36700531 | A Man With Dyslipidemia: To Treat Or Not To Treat? |
Q50320306 | A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice. |
Q37672465 | A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids |
Q30048180 | A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations |
Q38106667 | A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. |
Q43167802 | A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis |
Q46973482 | A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus |
Q37179792 | A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies |
Q46796677 | A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet |
Q28472432 | A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials |
Q38113494 | A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs |
Q33569334 | A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants |
Q38575410 | A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. |
Q36011053 | A review of time courses and predictors of lipid changes with fenofibric acid-statin combination |
Q91197948 | A robust method to estimate regional polygenic correlation under misspecified linkage disequilibrium structure |
Q28282265 | A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes |
Q40104818 | ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy |
Q37851958 | AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types |
Q43043483 | Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. |
Q90573977 | Absolute Quantification of Apolipoproteins Following Treatment with Omega-3 Carboxylic Acids and Fenofibrate Using a High Precision Stable Isotope-labeled Recombinant Protein Fragments Based SRM Assay |
Q34291764 | Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study |
Q55401962 | Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism. |
Q37699483 | Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production |
Q36842486 | Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor |
Q43058588 | Acute renal failure with the combined use of rosuvastatin and fenofibrate |
Q38236677 | Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia |
Q36976354 | Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study). |
Q34319662 | Advances in diabetic retinopathy |
Q38088818 | Advances in our understanding of diabetic retinopathy. |
Q37104870 | Advances in the management of hyperlipidemia-induced atherosclerosis |
Q36329908 | Advances in the treatment of nonalcoholic fatty liver disease |
Q37761373 | Advancing therapy for hypercholesterolemia |
Q46822559 | After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? |
Q46162422 | Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design |
Q45420980 | All at sea: new lipid-lowering drug trials continue to disappoint |
Q31101617 | All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. |
Q26798068 | Alteration of Fatty Acid Oxidation in Tubular Epithelial Cells: From Acute Kidney Injury to Renal Fibrogenesis |
Q42711225 | American College of Endocrinology Pre-Diabetes Consensus Conference: part two. |
Q33610712 | American Diabetes Association indications for statins in diabetes: is there evidence? |
Q34608277 | An ACACB variant implicated in diabetic nephropathy associates with body mass index and gene expression in obese subjects |
Q36328050 | An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). |
Q35569823 | An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature |
Q48849892 | An evaluation of diabetes-related measures of control after 6 months of clinical pharmacy specialist intervention. |
Q37942705 | An old friend in a new light: the role of osteocalcin in energy metabolism |
Q38032616 | An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels |
Q35050146 | An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes |
Q29999973 | Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction |
Q34283036 | Anti-angiogenic treatment strategies for the therapy of endometriosis |
Q37139567 | Antidiabetic action of bezafibrate in a large observational database |
Q38296685 | Antilipidemic Drug Therapy Today and in the Future |
Q98153760 | Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice? |
Q83308503 | Approach to lipid therapy in the patient with atherosclerotic vascular disease |
Q28209964 | Approaches to prevention of cardiovascular complications and events in diabetes mellitus |
Q35042647 | Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. |
Q91038198 | Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial |
Q90145015 | Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials |
Q37281210 | Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence |
Q38383033 | Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes |
Q37448563 | Association of Postbreakfast Triglyceride and Visit-to-Visit Annual Variation of Fasting Plasma Glucose with Progression of Diabetic Nephropathy in Patients with Type 2 Diabetes |
Q93007473 | Associations between Triglyceride-Glucose Index and Micro- and Macro-angiopathies in Type 2 Diabetes Mellitus |
Q48229572 | Atherogenic Lipoprotein Subfractions and Carotid Atherosclerosis in Menopausal Women. |
Q33776194 | Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials |
Q34139042 | Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena? |
Q37119482 | Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study. |
Q28200554 | Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins |
Q28538861 | Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL |
Q37049636 | Atherosclerosis and cardiovascular risk reduction with PPAR agonists |
Q37832648 | Atherosclerosis in 2010: new therapeutic insights |
Q35525108 | Atherosclerosis in systemic lupus erythematosus |
Q34730108 | Atherosclerosis in type 2 diabetes: a role for fibrate therapy? |
Q37786650 | Atherosclerosis regression and high-density lipoproteins |
Q37770113 | Atherosclerosis, diabetes and lipoproteins |
Q64901460 | Atorvastatin and Fenofibrate Increase the Content of Unsaturated Acyl Chains in HDL and Modify In Vivo Kinetics of HDL-Cholesteryl Esters in New Zealand White Rabbits. |
Q45238669 | Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients |
Q46252246 | Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. |
Q51492959 | Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. |
Q47801721 | Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong |
Q36820247 | Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update |
Q36796520 | Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise |
Q24642372 | Avosentan reduces albumin excretion in diabetics with macroalbuminuria |
Q35809770 | Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies |
Q41995332 | Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy |
Q26853571 | Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes |
Q35688214 | Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. |
Q36014419 | Best practice in primary care pathology: review 7. |
Q84971211 | Beyond statin therapy: a review of the management of residual risk in diabetes mellitus |
Q38100747 | Beyond statins: lipid management to reduce cardiovascular risk |
Q37199135 | Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism |
Q36489752 | Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial |
Q34422821 | Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study |
Q57819059 | Bilirubin, a Cardiometabolic Signaling Molecule |
Q51422622 | Blinded assessment of treatment effects for survival endpoint in an ongoing trial. |
Q33908782 | Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB |
Q36049377 | CYP4A11 variant is associated with high-density lipoprotein cholesterol in women |
Q36593266 | Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease |
Q47557757 | Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment |
Q38176275 | Cardiometabolic impact of non-statin lipid lowering therapies |
Q37161933 | Cardiometabolic interventions - focus on transcriptional regulators |
Q37702722 | Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease |
Q57931390 | Cardiovascular Disease and Diabetes: Two Sides of the Same Coin! |
Q52571293 | Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. |
Q42398936 | Cardiovascular disease and glycemic treatment |
Q37688153 | Cardiovascular disease is preventable among women |
Q36679594 | Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents |
Q39420208 | Cardiovascular disease prevention strategies for type 2 diabetes mellitus |
Q36419283 | Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities |
Q37803337 | Cardiovascular drug therapy in the elderly: benefits and challenges |
Q36772880 | Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease |
Q37577148 | Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations |
Q37811044 | Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. |
Q40100018 | Cardiovascular risk and dyslipidemia among persons living with HIV: a review |
Q37877789 | Cardiovascular risk in diabetic end-stage renal disease patients |
Q26998699 | Challenges in elucidating the genetics of diabetic retinopathy |
Q51301866 | Challenges in the treatment of hypertriglyceridemia: glass half empty or half full? |
Q37173568 | Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy |
Q86553722 | Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD |
Q86553726 | Chapter 5: Referral to specialists and models of care |
Q87393564 | Chapter 5: Triglyceride-lowering treatment in adults |
Q44521282 | Cholesterol goals: moving from numbers to treatment |
Q37030666 | Cholesterol trials and mortality |
Q46971473 | Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region |
Q33286262 | Cholesterol--when is lower better? |
Q61799320 | Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week |
Q33590777 | Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors |
Q33722806 | Circadian rhythms and metabolic syndrome: from experimental genetics to human disease. |
Q64075657 | Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases |
Q89585086 | Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy |
Q33900204 | Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges |
Q37011769 | Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations |
Q95633714 | Clinical approach to the inflammatory etiology of cardiovascular diseases |
Q38420505 | Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis |
Q36379507 | Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy: current status and future prospects |
Q36675450 | Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles |
Q35070830 | Clinician's guide to the updated ABCs of cardiovascular disease prevention |
Q53087837 | Clinician-trialist rounds: 5. Cointervention bias--how to diagnose it in their trial and prevent it in yours. |
Q28728567 | Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy |
Q38063295 | CoQ10 and L-carnitine for statin myalgia? |
Q88868163 | Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events |
Q37842472 | Combination lipid therapy in type 2 diabetes mellitus |
Q37663503 | Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study |
Q35101789 | Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial |
Q34231611 | Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction |
Q37103948 | Combination therapy in the management of mixed dyslipidaemia |
Q37855939 | Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus |
Q37857866 | Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism |
Q46126670 | Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment. |
Q28659915 | Common variants associated with plasma triglycerides and risk for coronary artery disease |
Q39593365 | Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea |
Q33956562 | Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care |
Q47392228 | Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease |
Q39367068 | Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors |
Q37206677 | Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial |
Q36831038 | Comparison of Effectiveness and Safety of Add-on Therapy of Saroglitazar and Fenofibrate with Metformin in Indian Patients with Diabetic Dyslipidaemia |
Q58102300 | Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes |
Q36528535 | Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087 |
Q33577611 | Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia |
Q47236264 | Computational and experimental investigation of DNA repair protein photolyase interactions with low molecular weight drugs. |
Q38232357 | Congenital lipodystrophies and dyslipidemias |
Q34980772 | Consensus statement on management of dyslipidemia in Indian subjects |
Q38815387 | Coronary Computed Tomography Angiography for Screening in Patients with Diabetes: Can Enhanced Detection of Subclinical Coronary Atherosclerosis Improve Outcome? |
Q46914500 | Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia |
Q36911699 | Coronary heart disease and cardiovascular autonomic neuropathy in the elderly diabetic |
Q51930537 | Correction to the FIELD study report. |
Q38186099 | Critical review of non-statin treatments for dyslipoproteinemia. |
Q35942012 | Cross Talk between Lipid Metabolism and Inflammatory Markers in Patients with Diabetic Retinopathy |
Q38124404 | Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia |
Q38546242 | Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs |
Q38338437 | Current drug treatment of hyperlipidemia in older adults. |
Q33646780 | Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia |
Q37196514 | Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease |
Q36970318 | Current strategies for ischemic stroke prevention: role of multimodal combination therapies |
Q36911423 | Cytochrome P450--physiological key factor against cholesterol accumulation and the atherosclerotic vascular process |
Q37775820 | Darapladib: an emerging therapy for atherosclerosis |
Q41998111 | Deciphering molecular mechanism underlying hypolipidemic activity of echinocystic Acid |
Q90748230 | Defective Mitochondrial Fatty Acid Oxidation and Lipotoxicity in Kidney Diseases |
Q38141575 | Demystifying the management of hypertriglyceridaemia. |
Q34014812 | Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis |
Q27654470 | Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists |
Q93160429 | Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - |
Q34530098 | Diabetes & coronary heart disease: current perspectives |
Q26750905 | Diabetes Dyslipidemia |
Q26782844 | Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research |
Q36783914 | Diabetes and cardiovascular disease: when it comes to lipids, statins are all you need |
Q42584933 | Diabetes and lipid lowering: where are we? |
Q30528669 | Diabetes in older adults |
Q34308751 | Diabetes in older adults: a consensus report |
Q39427190 | Diabetes mellitus and stroke: A clinical update |
Q37984922 | Diabetes, hyperglycaemia, and acute ischaemic stroke |
Q83474625 | Diabetes: Should we use fibrates in patients with diabetes and mild CKD? |
Q33446544 | Diabetes: managing dyslipidaemia |
Q57475590 | Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies |
Q37119313 | Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials |
Q81315582 | Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials |
Q37757979 | Diabetic dyslipidemia: extending the target beyond LDL cholesterol |
Q96172012 | Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group |
Q34790721 | Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic |
Q34498235 | Diabetic retinopathy: pathogenesis, clinical grading, management and future developments |
Q33302529 | Diabetic retinopathy: treatment and prevention |
Q55109775 | Diabetische Retinopathie |
Q37737551 | Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. |
Q36964616 | Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol. |
Q35895453 | Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics |
Q39214885 | Distinct but complementary contributions of PPAR isotypes to energy homeostasis. |
Q37972824 | Do persons with diabetes benefit from combination statin and fibrate therapy? |
Q37119260 | Do statins reduce events in patients with metabolic syndrome? |
Q40082318 | Does IMPROVE-IT prove it? |
Q33776187 | Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? |
Q37355471 | Does reversal of oxidative stress and inflammation provide vascular protection? |
Q37119252 | Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? |
Q36712986 | Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors |
Q46199518 | Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids |
Q36438737 | Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy |
Q37771014 | Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs |
Q35903126 | Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis |
Q36718446 | Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide |
Q40017196 | Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. |
Q26774903 | Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics |
Q38773023 | Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy |
Q37291520 | Dyslipidaemia as a predictor of hypertension in middle-aged men. |
Q87602479 | Dyslipidaemia in perspective |
Q50180407 | Dyslipidaemia in the elderly: to treat or not to treat? |
Q35029623 | Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment |
Q54394383 | Dyslipidaemia: Small triumph for fenofibrate therapy in dyslipidaemia. |
Q38777322 | Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease |
Q38508952 | Dyslipidemia and cardiovascular disease in women |
Q37311034 | Dyslipidemia and cardiovascular risk: the importance of early prevention |
Q26851294 | Dyslipidemia and its therapeutic challenges in renal transplantation |
Q36839937 | Dyslipidemia in type 2 diabetes mellitus |
Q46116452 | Dyslipidemia in type 2 diabetes mellitus |
Q38088216 | Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management |
Q33776181 | Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. |
Q38049066 | Dyslipidemia: management using optimal lipid-lowering therapy |
Q22241786 | ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary |
Q38325814 | Early investigational drugs targeting PPAR-α for the treatment of metabolic disease |
Q41001502 | Editorial on hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol goals in diabetics |
Q41223740 | Effect of Fenofibrate Medication on Renal Function |
Q35146964 | Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression |
Q90481227 | Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial |
Q90481174 | Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinica |
Q91934331 | Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial |
Q51385582 | Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose. |
Q37206183 | Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial |
Q59796327 | Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials |
Q33305306 | Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. |
Q51745604 | Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. |
Q59335245 | Effect of fenofibrate on uric acid level in patients with gout |
Q47388747 | Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers |
Q37484551 | Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome |
Q33686312 | Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients. |
Q36013120 | Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels. |
Q38089207 | Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development. |
Q38856838 | Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review |
Q56558843 | Effect of preischemic treatment with fenofibrate, a peroxisome proliferator-activated receptor-α ligand, on hepatic ischemia-reperfusion injury in rats |
Q30364133 | Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. |
Q37064893 | Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats |
Q28244205 | Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients |
Q36295672 | Effectiveness of Integrated Care on Delaying Progression of stage 3-4 Chronic Kidney Disease in Rural Communities of Thailand (ESCORT study): a cluster randomized controlled trial |
Q35498269 | Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse |
Q58384543 | Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study |
Q36005146 | Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia |
Q48209248 | Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. |
Q30353176 | Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle? |
Q90202860 | Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis |
Q34262967 | Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study |
Q83549170 | Effects of combination lipid therapy in diabetes mellitus |
Q33889260 | Effects of combination lipid therapy in type 2 diabetes mellitus |
Q38293501 | Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function |
Q79778566 | Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects |
Q34282749 | Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting |
Q42586832 | Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants |
Q57274310 | Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study |
Q37105236 | Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study |
Q45535226 | Effects of fibrates on cardiovascular outcomes |
Q33576435 | Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. |
Q33442332 | Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice |
Q79843492 | Effects of long-term fenofibrate therapy on cardiovascular events in people with type 2 diabetes mellitus |
Q33602077 | Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy |
Q50535809 | Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study. |
Q51470916 | Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. |
Q36909527 | Effects of pioglitazone on lipid and lipoprotein metabolism |
Q37594830 | Effects of preventive acupuncture and moxibustion on fat accumulation, blood lipid, and uterus e 2 of menopause rats. |
Q35189566 | Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study |
Q37578267 | Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study |
Q52599940 | Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. |
Q98613627 | Efficacy and Safety of Prescription Omega-3 Fatty Acids Added to Stable Statin Therapy in Korean Patients with Type 2 Diabetes and Hypertriglyceridemia: a Randomized Controlled Trial |
Q38382774 | Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multic |
Q37509280 | Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease |
Q46973474 | Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes |
Q46810258 | Elevated serum creatinine levels associated with fenofibrate therapy |
Q55710149 | Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, Oxidized LDL, adiponectin, and uric acid. |
Q38263909 | Emerging drugs for hyperlipidaemia: an update |
Q38293506 | Emerging small molecule drugs |
Q38217102 | Emerging therapeutic approaches to treat dyslipidemia |
Q37812007 | Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure |
Q38086841 | Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy |
Q37288105 | Established and emerging approaches for the management of dyslipidaemia |
Q84612643 | Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study |
Q35987990 | Estimation of adjusted rate differences using additive negative binomial regression |
Q36736169 | Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management |
Q64285261 | Evaluating All Potential Oral Complications of Diabetes Mellitus |
Q24608464 | Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline |
Q52721054 | Evaluation of lipid profile and its relationship with blood pressure in patients with Cushing's disease. |
Q83749876 | Evidence-based medicine and the selection of lipid-lowering therapy in type 2 diabetes |
Q34630829 | Evolution of peroxisome proliferator-activated receptor agonists |
Q38058381 | Examining the safety of PPAR agonists - current trends and future prospects |
Q38219487 | Expanded colesevelam administration options with oral suspension formulation for patients with diabetes and hypercholesterolemia |
Q90722135 | Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence |
Q36087108 | Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation |
Q38011204 | Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety. |
Q36847314 | Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia? |
Q36522005 | FIELD study |
Q36703114 | Facts and principles learned at the 39th Annual Williamsburg Conference on Heart Disease |
Q30917948 | Fall in population-based mortality from coronary heart disease negated in people with diabetes mellitus: data from England |
Q44206732 | Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. |
Q37605212 | Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis |
Q30248492 | Fenofibrate and Diabetic Retinopathy |
Q46909170 | Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD). |
Q80804741 | Fenofibrate and diabetic retinopathy |
Q40777122 | Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. |
Q37612824 | Fenofibrate and metabolic syndrome |
Q45998863 | Fenofibrate and risk of minor amputations in diabetes. |
Q38088377 | Fenofibrate and the kidney: an overview. |
Q42377473 | Fenofibrate decreases the bone quality by down regulating Runx2 in high-fat-diet induced Type 2 diabetes mellitus mouse model. |
Q37331280 | Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner |
Q37297015 | Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stress |
Q33305305 | Fenofibrate for diabetic retinopathy |
Q37681585 | Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study |
Q57190536 | Fenofibrate improves vascular endothelial function and contractility in diabetic mice |
Q33912957 | Fenofibrate in primary biliary cirrhosis: a pilot study. |
Q37554863 | Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial |
Q37770249 | Fenofibrate in the treatment of dyslipidemia associated with HIV infection. |
Q37238488 | Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension |
Q33642616 | Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway |
Q42281309 | Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases |
Q33736139 | Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome |
Q41605028 | Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats |
Q83306839 | Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis |
Q30419020 | Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience |
Q38118853 | Fenofibrate-associated nephrotoxicity: a review of current evidence |
Q37653029 | Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy |
Q28220294 | Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review |
Q33933474 | Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus |
Q95794110 | Fenofibrate: a review of its use in dyslipidaemia |
Q36702091 | Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus |
Q37329141 | Fenofibrate: treatment of hyperlipidemia and beyond |
Q37992119 | Fenofibric acid for hyperlipidemia |
Q35221085 | Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability |
Q28284661 | Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia |
Q90377775 | Fibrate pharmacogenomics: expanding past the genome |
Q37576105 | Fibrate therapy and renal function |
Q36562239 | Fibrate therapy in patients with metabolic syndrome and diabetes mellitus |
Q37771902 | Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found |
Q37704392 | Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid |
Q94454408 | Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction |
Q36679599 | Fibrates after the FIELD study: Some answers, more questions |
Q42218338 | Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2. |
Q35889448 | Fibrates and cholestasis |
Q28287250 | Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease |
Q38260501 | Fibrates and niacin: is there a place for them in clinical practice? |
Q21246041 | Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction |
Q30241199 | Fibrates for primary prevention of cardiovascular disease events. |
Q24186376 | Fibrates for secondary prevention of cardiovascular disease and stroke |
Q24204000 | Fibrates for secondary prevention of cardiovascular disease and stroke |
Q24195161 | Fibrates for type 2 diabetes mellitus |
Q24204016 | Fibrates for type 2 diabetes mellitus |
Q43050781 | Fibrates in CVD: a step towards personalised medicine |
Q36366283 | Fibrates in combination with statins in the management of dyslipidemia |
Q49571281 | Fibrates in the management of atherogenic dyslipidemia. |
Q84960836 | Fibrates reduce the risk of major cardiovascular and coronary events compared with placebo, but do not affect risk of cardiovascular or all-cause mortality |
Q28279732 | Fibrates, glitazones, and peroxisome proliferator-activated receptors |
Q36742410 | Fibrates: what have we learned in the past 40 years? |
Q37368691 | Fibrates: where are we now? |
Q40330590 | Field of confusion: future prospects for fibrate therapy in cardiovascular disease |
Q37196864 | First Prospective Cohort Study of Diabetic Retinopathy from Sub-Saharan Africa: High Incidence and Progression of Retinopathy and Relationship to Human Immunodeficiency Virus Infection |
Q61451411 | Gemfibrozil reduces lipid accumulation in SMMC-7721 cells via the involvement of PPARα and SREBP1 |
Q44874088 | Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. |
Q36573908 | Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction |
Q34000840 | Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment |
Q28070152 | Glycaemic Effects of Non-statin Lipid-Lowering Therapies |
Q35898200 | Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. |
Q37251490 | Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association |
Q93109141 | HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk |
Q30251918 | HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation |
Q38739884 | HDL cholesterol: reappraisal of its clinical relevance |
Q38195221 | HDL hypothesis: where do we stand now? |
Q38391229 | HDL particle subpopulations: Focus on biological function |
Q38217089 | HDL: to treat or not to treat? |
Q37018213 | HIV-associated dyslipidaemia: pathogenesis and treatment |
Q53088204 | HRT and breast cancer risk: a realistic perspective. |
Q37847616 | Haem oxygenase-1 and cardiovascular disease: mechanisms and therapeutic potential |
Q36807491 | Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction |
Q35975150 | Hepatic Cerebroside Sulfotransferase Is Induced by PPARα Activation in Mice |
Q43817772 | Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. |
Q42953260 | High Density Lipoprotein Turnover is Dependent on Peroxisome Proliferator-Activated Receptor α in Mice |
Q28476672 | High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy |
Q37264429 | High density lipoprotein: a therapeutic target in type 2 diabetes |
Q34313937 | High density lipoproteins-based therapies for cardiovascular disease |
Q45947888 | High dietary methionine plus cholesterol stimulates early atherosclerosis and late fibrous cap development which is associated with a decrease in GRP78 positive plaque cells. |
Q83426043 | High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia |
Q34637683 | High prevalence in Malawi of sight-threatening retinopathy and visual impairment caused by diabetes: identification of population-specific targets for intervention |
Q90006079 | High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk |
Q38965138 | High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. |
Q35844499 | High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome |
Q37400405 | High-density lipoprotein cholesterol: current perspective for clinicians |
Q37707412 | High-density lipoproteins and cardiovascular disease: 2010 update |
Q36892501 | Homocysteine and cardiovascular disease: a review of the evidence |
Q37424324 | Homocysteine and lipids: S-adenosyl methionine as a key intermediate |
Q36889170 | How can we prevent cardiovascular disease in diabetes |
Q37004718 | Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease |
Q37677038 | Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice |
Q36609968 | Hyperlipidemia as a risk factor for cardiovascular disease |
Q34045514 | Hyperlipidemia medication management in patients admitted for a myocardial infarction |
Q37861888 | Hypertension and lipid management in prediabetic states |
Q49894643 | Hypertension with diabetes mellitus complications. |
Q39181612 | Hypertriglyceridaemia and risk of coronary artery disease |
Q92793323 | Hypertriglyceridaemia predicts subsequent long-term risk of cardiovascular events in Chinese adults: 23-year follow-up of the Daqing Diabetes Study |
Q60533968 | Hypertriglyceridemia |
Q47180199 | Hypertriglyceridemia and atherosclerosis |
Q88697605 | Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding |
Q55176268 | Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. |
Q37058951 | Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy |
Q24672914 | Hypertriglyceridemia: its etiology, effects and treatment |
Q30244825 | Hypertriglyceridemia: the importance of identifying patients at risk |
Q60727742 | Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals |
Q41726958 | ISN Forefronts Symposium 2015: Nuclear Receptors and Diabetic Nephropathy |
Q37464513 | Iatrogenic severe depression of high-density lipoprotein cholesterol |
Q47422605 | Identification and Characterization of Fenofibrate-Induced Liver Injury |
Q37682488 | Identification of Patients With Diabetes Who Benefit Most From a Health Coaching Program in Chronic Disease Management, Sydney, Australia, 2013. |
Q33940875 | Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD. |
Q35567828 | Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs |
Q36701499 | Impact of diabetes on cardiovascular disease: an update |
Q34901492 | Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents |
Q42943434 | Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study |
Q37704388 | Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy |
Q35777145 | Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial |
Q88477468 | Impact of the triglyceride level on coronary plaque components in female patients with coronary artery disease treated with statins |
Q43029247 | Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going? |
Q37201658 | Importance of achieving the composite endpoints in diabetes |
Q34620714 | Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective |
Q36018677 | In vitro antimalarial activity and drug interactions of fenofibric acid |
Q37577126 | In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion |
Q38198762 | Incidence and precipitants of hospitalization for pancreatitis in people with diabetes: the Fremantle Diabetes Study |
Q39942361 | Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study |
Q41214273 | Incidence and progression of diabetic retinopathy in Sub-Saharan Africa: A five year cohort study. |
Q47844045 | Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. |
Q36721159 | Increased Rosuvastatin Dose versus Concomitant Fenofibrate and Rosuvastatin Therapy to Achieve Lipid Goal in Patients with Diabetes or Atherosclerosis with Metabolic Syndrome |
Q34541793 | Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database |
Q37701553 | Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease |
Q92859105 | Individualised screening for diabetic retinopathy: the ISDR study-rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening |
Q85895949 | Inducing effect of clofibric acid on stearoyl-CoA desaturase in intestinal mucosa of rats |
Q38786058 | Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis |
Q38831490 | Influence of HDL particles on cell-cholesterol efflux under various pathological conditions |
Q34149881 | Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats |
Q93049588 | Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia |
Q35936964 | Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia. |
Q81312274 | Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose |
Q26740443 | Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders |
Q34698887 | Insulin resistance and atherosclerosis |
Q36966063 | Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. |
Q49908591 | Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance. |
Q37964753 | Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? |
Q39892570 | Is fenofibrate a cost-saving treatment for middle-aged individuals with type 2 diabetes? A South African private-sector perspective |
Q30372692 | Is fenofibrate a reasonable treatment for diabetic microvascular disease? |
Q35624965 | Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study |
Q37073546 | Is raising HDL a futile strategy for atheroprotection? |
Q36640581 | Is the metabolic syndrome a real clinical entity and should it receive drug treatment? |
Q35871962 | Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? |
Q46237709 | Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins? |
Q58362346 | Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 |
Q55069710 | Japanese Clinical Practice Guideline for Diabetes 2016. |
Q37245464 | Kidney function and estimated vascular risk in patients with primary dyslipidemia |
Q38240747 | LDL cholesterol: controversies and future therapeutic directions |
Q37307992 | LDL reduction: how low should we go and is it safe? |
Q64355400 | LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study |
Q30248925 | LDL-Cholesterol: Standards of Treatment 2016: A German Perspective |
Q35747811 | LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia |
Q90079595 | Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study |
Q28579542 | Leptin induces hypertrophy through activating the peroxisome proliferator‐activated receptor α pathway in cultured neonatal rat cardiomyocytes |
Q92150307 | Life Style Intervention Improves Retinopathy Status-The Finnish Diabetes Prevention Study |
Q57182351 | Linking diabetes and atherosclerosis |
Q27024982 | Lipid abnormalities in kidney disease and management strategies |
Q39097856 | Lipid and other management to improve arterial disease and survival in end stage renal disease |
Q35285568 | Lipid biology of the podocyte--new perspectives offer new opportunities |
Q37853015 | Lipid control in patients with diabetes mellitus |
Q84393166 | Lipid disorders in type 2 diabetes |
Q42425149 | Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits |
Q37810593 | Lipid lowering for secondary prevention of cardiovascular disease in older adults |
Q34530349 | Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention |
Q38248011 | Lipid mediators in diabetic nephropathy |
Q43058605 | Lipid-lowering agents and new onset diabetes mellitus |
Q87170468 | Lipid-lowering agents in chronic kidney disease: do fibrates have a role? |
Q37576110 | Lipid-lowering drugs and risk for cancer |
Q38699252 | Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening |
Q36573878 | Lipid-lowering effects of statins: a comparative review |
Q38222135 | Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. |
Q46809610 | Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. |
Q37619497 | Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges |
Q35232239 | Lipid-lowering therapy in older persons |
Q37084296 | Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention |
Q26827432 | Lipid-lowering therapy: who can benefit? |
Q37900938 | Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. |
Q53205337 | Lipids and Diabetic Retinopathy. |
Q37961883 | Lipids and diabetic retinopathy |
Q36586503 | Lipotoxicity |
Q39584105 | Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score |
Q50893620 | Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. |
Q36334542 | Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study |
Q40471167 | Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. |
Q43448661 | Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20). |
Q35650429 | Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin |
Q36904436 | Low-density lipoprotein cholesterol in high-risk asymptomatic individuals |
Q57796293 | Lower extremity arterial disease in patients with diabetes: a contemporary narrative review |
Q36587615 | Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients |
Q33890208 | Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus |
Q35230819 | Lowering triglycerides to modify cardiovascular risk: will icosapent deliver? |
Q55464963 | Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. |
Q37750261 | Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome |
Q36902774 | Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome |
Q36865071 | Management of coronary artery disease in patients with type 2 diabetes mellitus |
Q64262692 | Management of diabetic dyslipidemia: An update |
Q79196435 | Management of diabetic dyslipidemia: doing the right thing |
Q62493181 | Management of diabetic retinopathy |
Q33402889 | Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality? |
Q35772115 | Management of dyslipidaemias |
Q37707165 | Management of dyslipidemia in people with type 2 diabetes mellitus |
Q38039980 | Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. |
Q34068746 | Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. |
Q36412642 | Management of extracranial carotid artery disease |
Q36646276 | Management of hypertension and dyslipidemia |
Q28219256 | Management of hypertension in patients with diabetes |
Q33935729 | Management of hypertriglyceridemia in the diabetic patient |
Q27009375 | Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway |
Q46714886 | Management of the metabolic syndrome in cardiovascular disease |
Q37385184 | Managing diabetic dyslipidemia: beyond statin therapy |
Q38934909 | Managing the lipid profile of coronary heart disease patients |
Q37012012 | Measuring biomarkers to assess the therapeutic effects of PPAR agonists? |
Q33528966 | Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice? |
Q89811716 | Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence |
Q38083007 | Medical management of stable coronary atherosclerosis. |
Q38085041 | Medical strategies to reduce amputation in patients with type 2 diabetes |
Q38290764 | Mendelian randomisation applied to drug development in cardiovascular disease: a review. |
Q30407506 | Mendelian randomization of blood lipids for coronary heart disease |
Q36054778 | Metabolic effects of a conversion from rosiglitazone to pioglitazone in Native American patients with type 2 diabetes. |
Q36916909 | Metabolic syndrome management |
Q37901053 | Metabolic syndrome: nature, therapeutic solutions and options |
Q36012953 | Metabolic syndrome: the danger signal in atherosclerosis |
Q60961572 | Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria |
Q33877294 | MicroRNAs are potential therapeutic targets in fibrosing kidney disease: lessons from animal models |
Q27026545 | MicroRNAs as potential therapeutic targets in kidney disease |
Q40274682 | Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes |
Q30548231 | Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study |
Q49886209 | Mitochondrial dysfunction in diabetic kidney disease. |
Q47958098 | Mitochondrial energetics in the kidney |
Q26859582 | Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy |
Q33942486 | Modified Lipoproteins in Diabetic Retinopathy: A Local Action in the Retina |
Q26829098 | Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects |
Q34594935 | Molecular Implications of the PPARs in the Diabetic Eye. |
Q34099937 | Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. |
Q37254899 | Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes |
Q38843479 | Monoclonal Antibodies for Lipid Management |
Q36366129 | Mortality rates in trials of subjects with type 2 diabetes |
Q36470320 | Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease |
Q43217643 | Multitherapy for diabetes |
Q93563258 | Multitherapy for diabetes |
Q34230175 | Nanopharmaceuticals (part 1): products on the market |
Q28072298 | New Era of Lipid-Lowering Drugs |
Q53401128 | New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies. |
Q90380337 | New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease |
Q37899907 | New approaches to the treatment of nephropathy in diabetes |
Q37956122 | New horizons for cholesterol ester transfer protein inhibitors |
Q47279052 | New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. |
Q36540320 | Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol |
Q44004071 | Niacin: the only vitamin that reduces cardiovascular events |
Q36329934 | No accord for the ACCORD-Lipid trial results |
Q33901914 | Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. |
Q38272551 | Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? |
Q37204025 | Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review |
Q100946503 | Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors |
Q28084156 | Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council |
Q46959415 | Normalization of metabolic syndrome using fenofibrate, metformin or their combination |
Q33751308 | Novel Pharmacologic Approaches for the Management of Diabetic Retinopathy |
Q46030429 | Novel action of 7-O-galloyl-D-sedoheptulose isolated from Corni Fructus as a hypertriglyceridaemic agent. |
Q37990618 | Novel pathways and therapies in experimental diabetic atherosclerosis |
Q34768716 | Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up |
Q60146019 | Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy |
Q38186327 | Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment |
Q38656281 | Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia |
Q30249819 | Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. |
Q34877739 | Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes |
Q37367669 | Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy |
Q38477187 | One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response |
Q38283386 | Ongoing challenges for pharmacotherapy for dyslipidemia |
Q24626884 | Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk |
Q81097348 | Optimal medical therapy with or without percutaneous coronary intervention for stable coronary disease: the COURAGE Study |
Q46494907 | Optimal treatment of the diabetic patient with multivessel disease |
Q53168850 | Optimizing lipid-lowering therapy in the prevention of coronary heart disease. |
Q51718394 | Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. |
Q26824004 | Origin and therapy for hypertriglyceridaemia in type 2 diabetes |
Q36561806 | Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis |
Q89207225 | PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review |
Q38586615 | PCSK9 Inhibitors: Are We on the Verge of a Breakthrough? |
Q26784482 | PCSK9 inhibition: the way forward in the treatment of dyslipidemia |
Q36444975 | PPAR Agonists and Cardiovascular Disease in Diabetes |
Q54936265 | PPAR Agonists and Metabolic Syndrome: An Established Role? |
Q42214835 | PPAR Medicines and Human Disease: The ABCs of It All. |
Q37996437 | PPAR agonists for the treatment of cardiovascular disease in patients with diabetes |
Q50773167 | PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. |
Q45974432 | PPAR-alpha and PPAR-gamma agonists for type 2 diabetes. |
Q39200940 | PPAR-α agonists are still on the rise: an update on clinical and experimental findings |
Q37616202 | PPAR-α as a key nutritional and environmental sensor for metabolic adaptation. |
Q61648721 | PPAR-α transcriptional activity is required to combat doxorubicin-induced podocyte injury in mice |
Q35000567 | PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans |
Q36154953 | PPARalpha in atherosclerosis and inflammation |
Q30390555 | PPARalpha: an emerging therapeutic target in diabetic microvascular damage. |
Q36889164 | PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? |
Q92128876 | PPARs as Nuclear Receptors for Nutrient and Energy Metabolism |
Q37362740 | PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury |
Q42820928 | PPARα agonist fenofibrate attenuates TNF-α-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway |
Q41911186 | PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists |
Q36536316 | PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. |
Q36807697 | Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. |
Q38757894 | Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment |
Q37861885 | Pathophysiology, prevention and management of chronic kidney disease in the hypertensive patient with diabetes mellitus. |
Q37340704 | Patient self-report of prior laser treatment reliably indicates presence of severe diabetic retinopathy |
Q37413789 | Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life |
Q92892621 | Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases |
Q37640263 | Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. |
Q36366326 | Peroxisome Proliferator-Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia |
Q48189776 | Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease. |
Q36261125 | Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions |
Q37992593 | Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes |
Q37583596 | Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? |
Q39982196 | Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein |
Q37861955 | Peroxisome proliferator-activated receptors and atherosclerosis. |
Q26866784 | Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review |
Q36845108 | Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes. |
Q37412297 | Peroxisome proliferator-activated receptors in diabetic nephropathy |
Q35636191 | Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease |
Q37016305 | Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease |
Q37012017 | Pharmacogenetics of the PPAR genes and cardiovascular disease |
Q42623314 | Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus |
Q34628781 | Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk |
Q39320400 | Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins |
Q36944008 | Pharmacologic therapeutics for cardiac reperfusion injury |
Q37357337 | Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus |
Q90445373 | Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence |
Q39015072 | Pharmacological management of diabetic dyslipidemia |
Q37842120 | Pharmacological strategies for lowering LDL cholesterol: statins and beyond |
Q38262435 | Pharmacological treatment and therapeutic perspectives of metabolic syndrome. |
Q38130111 | Pharmacotherapies for lipid modification: beyond the statins |
Q37801374 | Pharmacotherapy of dyslipidemias in the adult population |
Q84764505 | Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: how low can we go? |
Q57500367 | Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study |
Q34347027 | Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study |
Q57463626 | Plasmapheresis for hypertriglyceridemia: The association between blood viscosity and triglyceride clearance rate |
Q37472064 | Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment |
Q42164828 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia |
Q37549374 | PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. |
Q37639159 | Postprandial Hyperlipidemia and Remnant Lipoproteins |
Q92888992 | Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes |
Q37964751 | Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review |
Q39440767 | Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia |
Q47875819 | Practical aspects in the management of statin-associated muscle symptoms (SAMS). |
Q38014975 | Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia |
Q33956714 | Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study |
Q36648858 | Preventing microalbuminuria in patients with type 2 diabetes |
Q35013431 | Prevention and early detection of vascular complications of diabetes |
Q55154739 | Prevention and management of statin adverse effects: A practical approach for pharmacists. |
Q22241916 | Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association |
Q36734315 | Primary prevention of cardiovascular events and type 2 diabetes: should we prioritize our interventions? |
Q35622601 | Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study |
Q29619982 | Progress and challenges in translating the biology of atherosclerosis |
Q38839105 | Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. |
Q36536280 | Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study |
Q37494202 | Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review |
Q36383197 | Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets |
Q47868740 | Proteomics landscape of radiation-induced cardiovascular disease: somewhere over the paradigm |
Q38365322 | ROLE OF INSULIN SENSITIZERS ON CARDIOVASCULAR RISK FACTORS IN POLYCYSTIC OVARIAN SYNDROME: A META-ANALYSIS. |
Q34382652 | Racial/ethnic differences in dyslipidemia patterns |
Q34271942 | Raising HDL cholesterol in women. |
Q58123970 | Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME -2 Trial |
Q36920620 | Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy |
Q33578422 | Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial |
Q37892300 | Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus |
Q36410620 | Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. |
Q43201242 | Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus |
Q93609057 | References |
Q93609219 | References |
Q38160494 | Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes |
Q33572259 | Regulation of oxidative stress and cardioprotection in diabetes mellitus |
Q36345240 | Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study). |
Q36372677 | Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. |
Q38997960 | Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study |
Q83602703 | Relevance of the serum apolipoprotein ratio to diabetic retinopathy |
Q57956749 | Renal function and cardiovascular events: relevance of eGFR and albuminuria in patients with diabetes |
Q33359672 | Renal lesions in patients with type 2 diabetes: a puzzle waiting to be solved |
Q46981976 | Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. |
Q36968971 | Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges |
Q26996039 | Residual macrovascular risk in 2013: what have we learned? |
Q37622065 | Residual microvascular risk in diabetes: unmet needs and future directions |
Q39638361 | Retinal vascular calibre as a predictor of incidence and progression of diabetic retinopathy |
Q53165465 | Retinal vascular calibre, geometry and progression of diabetic retinopathy in type 2 diabetes mellitus. |
Q37565692 | Retinal vascular changes and diabetic retinopathy |
Q36823777 | Retinal vascular signs in diabetes and hypertension--review |
Q37702862 | Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes-Associated Retinopathy |
Q30419512 | Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants |
Q38239205 | Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies |
Q38430793 | Role for combination therapy in diabetic dyslipidemia |
Q39817316 | Role of PPARα and Its Agonist in Renal Diseases. |
Q38546383 | Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy |
Q34976710 | Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes |
Q53093527 | Role of fibrate drugs in the prevention of diabetic foot. |
Q37811855 | Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective |
Q27000731 | Role of lipotoxicity in endothelial dysfunction |
Q36802569 | Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia |
Q36889865 | Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus |
Q37973966 | Role of the PPAR-α agonist fenofibrate in severe pediatric burn |
Q48141985 | Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. |
Q37741779 | Role of triglyceride-rich lipoproteins in diabetic nephropathy |
Q46363801 | Rosiglitazone and pioglitazone in the treatment of diabetes mellitus |
Q41753267 | Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis |
Q34481529 | Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study |
Q38541832 | Safety considerations with fenofibrate/simvastatin combination. |
Q38352759 | Saroglitazar for the treatment of dyslipidemia in diabetic patients |
Q38041209 | Second line options for hyperlipidemia management after cardiac transplantation. |
Q48632120 | Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). |
Q46466078 | Secondary prevention after myocardial infarction |
Q37229876 | Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? |
Q37056590 | Secondary stroke prevention: inside the vessels and beyond |
Q36580568 | Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis |
Q38110581 | Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists |
Q56972590 | Serum LDL cholesterol levels and new onset of arterial hypertension: an 8-year follow-up |
Q91875427 | Serum lipid management in patients with type 1 and type 2 diabetes: a hospital-based cohort study |
Q45922693 | Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids. |
Q35111638 | Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants |
Q36446970 | Should We Use PPAR Agonists to Reduce Cardiovascular Risk? |
Q36415856 | Should all patients with metabolic syndrome be treated with statins? |
Q36422727 | Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence |
Q42915854 | Should niacin be the preferred drug to add to a statin? |
Q42945058 | Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study? |
Q37346390 | Should we start all patients with diabetic retinopathy on fenofibrates? |
Q46199534 | Should we treat all primary prevention patients with statins? |
Q36823774 | Silent myocardial ischemia screening in patients with diabetes mellitus |
Q39435430 | Simulating lifetime outcomes associated with complications for people with type 1 diabetes. |
Q39743309 | Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes |
Q33562131 | Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis |
Q36642327 | Small, dense low-density-lipoproteins and the metabolic syndrome. |
Q24541529 | Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis |
Q89537341 | Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date |
Q37036416 | Standards of medical care in diabetes--2009. |
Q33554238 | Standards of medical care in diabetes--2010. |
Q34425055 | Standards of medical care in diabetes--2011. |
Q24632533 | Standards of medical care in diabetes--2012 |
Q29620309 | Standards of medical care in diabetes--2013 |
Q38881156 | Statin combination therapy and cardiovascular risk reduction |
Q48145497 | Statin drug interactions and related adverse reactions: an update |
Q37351347 | Statin use and lower extremity amputation risk in nonelderly diabetic patients |
Q28083004 | Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management |
Q36900804 | Statins and C-reactive protein levels |
Q38020453 | Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes |
Q37757988 | Strategies for the development of new PPAR agonists in diabetes |
Q84121717 | Strategies to achieve target LDL levels |
Q36124203 | Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial |
Q38160901 | Summarizing the FIELD study: lessons from a 'negative' trial |
Q36602779 | Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis |
Q36712679 | Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series |
Q35067111 | Systemic medical management of diabetic retinopathy |
Q38904497 | Targeting ApoC-III to Reduce Coronary Disease Risk |
Q33809886 | Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs |
Q38846534 | Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm |
Q38431166 | Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance |
Q35084845 | Targeting metabolic disturbance in the diabetic heart |
Q90242473 | Targeting metabolic dysregulation for fibrosis therapy |
Q38880569 | Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy |
Q37242352 | Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice |
Q34695851 | Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. |
Q104500079 | Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial |
Q36783686 | The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses |
Q35871965 | The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus |
Q33390186 | The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein |
Q51321256 | The Combination of Elevated Triglycerides and Abnormal Fasting Glucose Increases Risk of Cerebral Infarction in Patients With Mild to Moderate Hypercholesterolemia: A Post Hoc Analysis of the MEGA Study. |
Q60955111 | The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases |
Q94475289 | The FIELD study |
Q83158057 | The FIELD study |
Q57475802 | The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk |
Q36478394 | The Functions of PPARs in Aging and Longevity |
Q41348534 | The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor |
Q64923599 | The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review. |
Q36445381 | The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects |
Q37311116 | The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient |
Q89534430 | The Rise and Fall "ing" of the HDL Hypothesis |
Q42292833 | The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus. |
Q30234550 | The Role of Emerging Risk Factors in Cardiovascular Outcomes |
Q52722809 | The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator 1α (PGC-1α) in Kidney Disease. |
Q98177451 | The Vicious Cycle of Renal Lipotoxicity and Mitochondrial Dysfunction |
Q42773416 | The causes and consequences of low levels of high density lipoproteins in patients with diabetes |
Q35295065 | The chylomicron: relationship to atherosclerosis |
Q37230691 | The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice |
Q37404473 | The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate |
Q35332645 | The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia |
Q37699675 | The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy. |
Q34615937 | The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study |
Q46973476 | The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes |
Q37978209 | The emerging role of HDL in glucose metabolism |
Q34042836 | The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies |
Q90197758 | The impact of artificial intelligence in the diagnosis and management of glaucoma |
Q36323280 | The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus |
Q46548609 | The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles |
Q36921672 | The importance of free fatty acids in the development of Type 2 diabetes. |
Q37132923 | The importance of treating cardiometabolic risk factors in patients with type 2 diabetes |
Q37000746 | The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes |
Q51372447 | The influence of risk factors for metabolic syndrome on vascular complications. |
Q33569142 | The metabolic syndrome |
Q37362674 | The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? |
Q38118163 | The need for combination drug therapies in patients with complex dyslipidemia |
Q38267131 | The new cholesterol treatment guidelines from the American College of Cardiology/American Heart Association, 2013: what clinicians need to know |
Q30380628 | The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. |
Q37079828 | The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. |
Q85718887 | The protective effect of fenofibrate against TNF-α-induced CD40 expression through SIRT1-mediated deacetylation of NF-κB in endothelial cells |
Q86057048 | The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study |
Q37997004 | The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes |
Q80139743 | The role of PPAR-alpha agonists in the prevention of CVD in diabetes |
Q36744879 | The role of Spectral Domain Optical Coherence Tomography in monitoring uncontrolled hypertensive type 2 diabetic patients |
Q46952308 | The role of fenofibrate in clinical practice |
Q24651324 | The role of genetics in susceptibility to diabetic retinopathy |
Q34730815 | The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer |
Q36936918 | The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes |
Q35060328 | The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Athe |
Q33776214 | The role of triglyceride in cardiovascular disease in asian patients with type 2 diabetes--a systematic review. |
Q36892498 | The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease |
Q36781520 | The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective |
Q36982574 | The treatment of dyslipidemia--what's left in the pipeline? |
Q95492629 | The use of fibric Acid derivatives in cardiovascular prevention |
Q35078274 | Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment |
Q35180084 | Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice |
Q37981725 | Therapeutic strategies to deplete macrophages in atherosclerotic plaques |
Q37825945 | Therapies for diabetic dyslipidaemia |
Q37464743 | Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials |
Q37144139 | Therapy and clinical trials: management of diabetic dyslipidemia |
Q28219591 | Therapy insight: peripheral arterial disease and diabetes--from pathogenesis to treatment guidelines |
Q46108030 | Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice |
Q37367666 | Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk |
Q57112903 | Towards more specific treatment for diabetic dyslipidemia |
Q41811073 | Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome. |
Q38201721 | Treating low high-density lipoprotein cholesterol: what is the evidence? |
Q36815978 | Treating the metabolic syndrome. |
Q35460295 | Treatment approaches for diabetes and dyslipidemia |
Q49689988 | Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. |
Q33887783 | Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes |
Q36079624 | Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status |
Q27026114 | Treatment of dyslipidemia |
Q34499472 | Treatment of dyslipidemia in patients with type 2 diabetes |
Q36975868 | Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors |
Q36560981 | Treatment of hypertriglyceridemia |
Q34099851 | Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087 |
Q92649743 | Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk |
Q37015549 | Triglyceride and cardiovascular risk: A critical appraisal |
Q57127377 | Triglyceride to HDL-cholesterol ratio as an independent risk factor for the poor development of coronary collateral circulation in elderly patients with ST-segment elevation myocardial infarction and acute total occlusion |
Q36151033 | Triglyceride to high-density lipoprotein cholesterol ratio predicts cardiovascular outcomes in prevalent dialysis patients. |
Q58550770 | Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy |
Q34181381 | Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management |
Q26745946 | Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease |
Q33610637 | Triglycerides and HDL cholesterol: stars or second leads in diabetes? |
Q37244736 | Triglycerides and risk for coronary artery disease |
Q91926577 | Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes |
Q38553671 | Tubular atrophy in the pathogenesis of chronic kidney disease progression |
Q34023548 | Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? |
Q36539101 | Type 2 diabetes and cardiovascular risk in the UK south Asian community. |
Q37153041 | Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors |
Q37104865 | Type 2 diabetes mellitus: prevention of macrovascular complications. |
Q26798326 | Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association |
Q27687851 | Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. |
Q37504704 | Update on strategies to increase HDL quantity and function |
Q37019924 | Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing |
Q36766923 | Update on the use of fibrates: focus on bezafibrate |
Q24678615 | Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? |
Q43490546 | Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes |
Q28548389 | Use of Fibrates Monotherapy in People with Diabetes and High Cardiovascular Risk in Primary Care: A French Nationwide Cohort Study Based on National Administrative Databases |
Q36623164 | Use of chronic disease management programs for diabetes: in Alberta's primary care networks. |
Q90338365 | Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study |
Q34428524 | Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials |
Q35903762 | Use of fibrates in the United States and Canada |
Q26765234 | Use of fibrates in the metabolic syndrome: A review |
Q97682129 | Use of non-LDL-C lipid-lowering medications in patients with type 2 diabetes |
Q89312828 | Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options |
Q57269550 | Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia |
Q30244247 | Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy |
Q36894180 | Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. |
Q46809067 | Waist-to-hip ratio correlates with homocysteine levels in male patients with coronary artery disease |
Q39388920 | We Know More Than We Can Tell About Diabetes and Vascular Disease: The 2016 Edwin Bierman Award Lecture |
Q100669091 | Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver |
Q37812296 | What combination therapy with a statin, if any, would you recommend? |
Q37961240 | What matters in ADVANCE and ADVANCE-ON. |
Q39528844 | What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients? |
Q93702607 | What's new in the other general journals |
Q35945237 | Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial |
Q38253965 | Why do statins reduce cardiovascular disease more than other lipid modulating therapies? |
Q37923968 | Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient? |
Q42707587 | World Congress on the insulin resistance syndrome, 2009: cellular mechanisms of insulin resistance |
Q42767776 | World congress on insulin resistance, diabetes, and cardiovascular disease: Part 1 |
Q43768587 | Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study. |
Q91975849 | Xuezhitong capsule, an extract of Allium macrostemon Bunge, exhibits reverse cholesterol transport and accompanies high-density lipoprotein levels to protect against hyperlipidemia in ApoE-/- mice |
Q42642151 | Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study |
Q52813315 | [Clinical importance of HDL cholesterol]. |
Q84952346 | [Diabetic nephropathy] |
Q87437305 | [Lipid therapy for patients with coronary heart disease and diabetes. Current state and perspectives] |
Q85725390 | [Lipids: diagnosis and therapy in type 2 diabetes] |
Q88025019 | [Part I. Fibrates in primary and secondary prevention] |
Q88025020 | [Part II. Combination statin plus fibrate regimens (free and fixed)] |
Q88025022 | [Part III. Clinical control of fenofibrate therapy] |
Q39245270 | cAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogenesis |
Q38559352 | α-Lipoic acid as a triglyceride-lowering nutraceutical |
Search more.